HDAC9 and nodal marginal zone B-cell lymphoma: Such mutations in epigenetic regulators were previously reported to be present in approximately 40% of NMZL [10] and may provide therapeutic opportunities using agents such as histone deacetylase (HDAC) inhibitors.